A Study of Gaboxadol in Primary Insomnia
Phase 3
Completed
- Conditions
- Primary Insomnia
- Registration Number
- NCT00209846
- Lead Sponsor
- H. Lundbeck A/S
- Brief Summary
To evaluate the safety and tolerability of gaboxadol in primary insomnia.
- Detailed Description
To obtain long-term safety data in elderly patients with gaboxadol.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 320
Inclusion Criteria
- patients with a diagnosis of primary insomnia
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Safety Tolerability
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of gaboxadol in treating primary insomnia?
How does gaboxadol compare to standard-of-care hypnotics in elderly insomnia patients?
Are there specific biomarkers that predict response to gaboxadol in primary insomnia?
What are the long-term adverse events associated with gaboxadol use in insomnia?
What is the therapeutic potential of gaboxadol compared to other GABAergic agents for insomnia?
Trial Locations
- Locations (1)
Non-US study, principal location:
🇸🇪Göteborg, Sweden
Non-US study, principal location:🇸🇪Göteborg, Sweden